Alnylam PharmaceuticalsLTS:0HD2 +0.99%67 Days Payable is 52.37 as of Mar. 2026, which is 70% below its 10-year median of 174.36. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $507.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 67.9% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alnylam Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Days Payable of 52.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alnylam Pharmaceuticals and its competitors. This is 70% below median its historical median of 174.36. Over the past decade, Alnylam Pharmaceuticals' Days Payable has ranged from 49.71 to 8,918.70. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #478 out of 704 companies in the Biotechnology industry, placing it in the top 67.9%.
Is Alnylam Pharmaceuticals' Days Payable too high?
Alnylam Pharmaceuticals' current Days Payable of 52.37 is 70% below median its 10-year median of 174.36. Over the past 10 years, this metric has ranged from a low of 49.71 to a high of 8,918.70. The Biotechnology industry median Days Payable is 113.56. Alnylam Pharmaceuticals' value of 52.37 is 53.9% below this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #478 out of 704 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Days Payable compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #478 out of 704 companies for Days Payable. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. Alnylam Pharmaceuticals' value of 52.37 is 53.9% below this benchmark. Historically, Alnylam Pharmaceuticals' own Days Payable has ranged from 49.71 to 8,918.70 over the past decade. While the company's 10-year median is 174.36 vs. the industry median of 113.56, Alnylam Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Days Payable of 52.37 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Days Payable is 52.37, which is 70% below median its own 10-year median of 174.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $507.34, compared to a current price of $297.28 — trading 41.4% below its estimated fair value. The current Days Payable is 52.37, which is 70% below median its 10-year median of 174.36 and 53.9% below the Biotechnology industry median of 113.56. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Days Payable is 52.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $297.28 is trading 41.4% below its estimated GF Value™ of $507.34.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Days Payable: 52.37 (70% below median its 10-year median of 174.36)
GF Value™: $507.34 vs. price of $297.28 (41.4% below fair value)
Industry Position: 53.9% below the Biotechnology median (#478 of 704)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
